DE602005023865D1 - N-phenylacryloylsubstituierte tyrosinderivate als agonisten von hppar-alpha und hppar-gamma - Google Patents

N-phenylacryloylsubstituierte tyrosinderivate als agonisten von hppar-alpha und hppar-gamma

Info

Publication number
DE602005023865D1
DE602005023865D1 DE602005023865T DE602005023865T DE602005023865D1 DE 602005023865 D1 DE602005023865 D1 DE 602005023865D1 DE 602005023865 T DE602005023865 T DE 602005023865T DE 602005023865 T DE602005023865 T DE 602005023865T DE 602005023865 D1 DE602005023865 D1 DE 602005023865D1
Authority
DE
Germany
Prior art keywords
hppar
phenylacryloyl
agonists
compound
gamma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005023865T
Other languages
English (en)
Inventor
Song Li
Xinbo Zhou
Lili Wang
Cheng Xu
Chengmai Ruan
Cuifang Lin
Junhai Xiao
Zhibing Zheng
Hongying Liu
Yunde Xie
Wu Zhong
Hao Cui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Molecule Science and Technology Co Ltd
Original Assignee
Beijing Molecule Science and Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Molecule Science and Technology Co Ltd filed Critical Beijing Molecule Science and Technology Co Ltd
Publication of DE602005023865D1 publication Critical patent/DE602005023865D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE602005023865T 2004-05-24 2005-03-02 N-phenylacryloylsubstituierte tyrosinderivate als agonisten von hppar-alpha und hppar-gamma Active DE602005023865D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNB2004100425741A CN100344618C (zh) 2004-05-24 2004-05-24 作为hPPARα和hPPARγ激动剂的N-芳丙烯酰基取代的酪氨酸衍生物
PCT/CN2005/000256 WO2005115999A1 (fr) 2004-05-24 2005-03-02 Derives de tyrosine remplaces par du n-phenylacryloyle utilises en tant qu'agonistes de hppar alpha et de hppar gama

Publications (1)

Publication Number Publication Date
DE602005023865D1 true DE602005023865D1 (de) 2010-11-11

Family

ID=35450817

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005023865T Active DE602005023865D1 (de) 2004-05-24 2005-03-02 N-phenylacryloylsubstituierte tyrosinderivate als agonisten von hppar-alpha und hppar-gamma

Country Status (7)

Country Link
US (1) US7781468B2 (de)
EP (1) EP1757596B1 (de)
CN (1) CN100344618C (de)
AT (1) ATE482937T1 (de)
DE (1) DE602005023865D1 (de)
ES (1) ES2352071T3 (de)
WO (1) WO2005115999A1 (de)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478582A (en) * 1994-02-08 1995-12-26 The Quaker Oats Company Dry mixture used for preparing a color-stable liquid composition
GB9817118D0 (en) 1998-08-07 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
CA2382966A1 (en) 1999-08-27 2001-03-08 Eli Lilly And Company Biaryl-oxa(thia)zole derivatives and their use as ppars modulators
PL361162A1 (en) * 2000-10-05 2004-09-20 Bayer Aktiengesellschaft Propionic acid derivatives with ppar-alpha activating properties
CZ20033037A3 (cs) * 2001-05-15 2004-06-16 F. Hoffmann-La Roche Ag Karboxylové kyselinou odvozené od substituovaných oxazolových derivátů pro použití jako PPAR-alfa a -gama aktivátory při léčbě diabetu
MXPA03010903A (es) * 2001-06-07 2004-02-17 Lilly Co Eli Moduladores de receptores activados por el proliferador de peroxisomas.

Also Published As

Publication number Publication date
EP1757596A1 (de) 2007-02-28
ES2352071T3 (es) 2011-02-15
CN100344618C (zh) 2007-10-24
EP1757596A4 (de) 2009-01-21
EP1757596B1 (de) 2010-09-29
CN1702070A (zh) 2005-11-30
US20080300286A1 (en) 2008-12-04
US7781468B2 (en) 2010-08-24
WO2005115999A1 (fr) 2005-12-08
ATE482937T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
ATE496622T1 (de) Verwendung von thienopyridonderivaten als ampk- aktivatoren und pharmazeutische zusammensetzungen,die diese enthalten
SE0402735D0 (sv) Novel compounds
PE20080251A1 (es) Usos de inhibidores de dpp iv
AR035631A1 (es) Compuestos quimicos
HUP0301749A2 (hu) Acilfenil-karbamid-származékok, eljárás az elżállításukra és gyógyszerkénti alkalmazásuk
CO6150170A2 (es) Derivados de 1-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indol y uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio
NO20091596L (no) Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
DE60036367D1 (de) Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
NO20083026L (no) Terapeutisk middel for diabetes
BRPI0511874A (pt) derivados da pirrolopiridina
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
CY1110316T1 (el) Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους
BRPI0418099A (pt) compostos, composição farmacêutica, e uso de um composto
BRPI0407253A (pt) Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos
DK1926729T3 (da) Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
RU2011117927A (ru) Карбаматное соединение или его соль
AR043259A1 (es) Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello
NO20070974L (no) Substituerte N-acyl-2-aminotiazoler
CO2024002748A2 (es) Profármaco de derivados de pirrolidona como activador de glucocinasa
BR0318533A (pt) azolidinacarbonitrilas e seu uso como inibidores de dpp-iv
DE602005023865D1 (de) N-phenylacryloylsubstituierte tyrosinderivate als agonisten von hppar-alpha und hppar-gamma
ATE391710T1 (de) Substituierte azetidinverbindungen als cyclooxigenase-1-cyclooxygenase-2-inhibitoren und deren herstellung und verwendung als medikament